NCT06138587View on ClinicalTrials.gov

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 24, 2024

Primary Completion Date

February 28, 2027

Study Completion Date

November 30, 2027

Conditions
Acute Myeloid LeukemiaLeukemiaLeukemia, MyeloidMyelodysplastic SyndromesMyeloproliferative NeoplasmMyeloproliferative Disorders
Interventions
BIOLOGICAL

Cytokine Induced Memory-like Natural Killer Cells

Allogeneic, cytokine induced memory-like natural killer cells, via intravenous infusion per protocol.

BIOLOGICAL

Interleukin-2

Recombinant, human glycoprotein, single-use 22 MIU vials, via subcutaneous injection per protocol.

Trial Locations (2)

02115

RECRUITING

Dana-Farber Cancer Institute, Boston

02215

NOT_YET_RECRUITING

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER